Infinity Pharmaceuticals, Inc.
GPTKB entity
Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Adelene_Perkins
|
| gptkbp:collaboratedWith |
gptkb:Roche
gptkb:Bristol_Myers_Squibb gptkb:Purdue_Pharma |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedDrug |
eganelisib
|
| gptkbp:focusesOn |
immuno-oncology
cancer therapeutics |
| gptkbp:founded |
1995
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Infinity Pharmaceuticals, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:researchArea |
oncology
PI3K pathway inhibitors |
| gptkbp:status |
gptkb:public_company
|
| gptkbp:stockSymbol |
gptkb:INFI
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.infi.com/
|
| gptkbp:bfsParent |
gptkb:INFI
|
| gptkbp:bfsLayer |
6
|